U.S. Food and Drug Administration Commissioner Scott Gottlieb on Wednesday announced the federal agency is creating a group to consider policy options regarding drug importation, according to a Forbes report.
The new effort is coming from a Gottlieb who in 2016 said Donald Trump’s proposal to import drugs from foreign countries would “offer consumers little relief.”
“We want to examine whether — under these narrow conditions — the additional market competition from the short-term importation of foreign versions of the drug may complement the FDA’s current efforts, and help meet near-term patient need in the U.S. until new competition is able to enter the domestic market,” Gottlieb said in a statement.
According to the Forbes report, the new group will look at a broad range of issues, including how the FDA will determine the seriousness of an access issue and how the agency will communicate with the Department of Health and Human Services to conduct a thorough evaluation of the need for importation.
To read the full report on Forbes, click here.